Olmesartan pharmacology
Pro Research Analysisby 
Searched over 200M research papers for "olmesartan pharmacology"
Olmesartan Pharmacology: Mechanism of Action and Receptor Selectivity
Olmesartan medoxomil is a prodrug that, after oral administration, is rapidly converted to its active form, olmesartan. Olmesartan is a highly potent, competitive, and selective antagonist of the angiotensin II type 1 (AT1) receptor, with minimal activity on AT2 and AT4 receptors. By blocking AT1 receptors in vascular smooth muscle and the adrenal gland, olmesartan prevents angiotensin II-induced vasoconstriction and aldosterone secretion, leading to reduced blood pressure and decreased sodium retention 1610.
Pharmacokinetics and Bioavailability of Olmesartan
After oral administration, olmesartan medoxomil is quickly absorbed and converted to olmesartan, which is not further metabolized. Peak plasma concentrations are reached within 1–3 hours, and the elimination half-life is 10–15 hours. The drug has a low volume of distribution, indicating limited tissue penetration, and about 40% of the absorbed dose is excreted by the kidneys, with the rest eliminated in feces via bile. The absolute bioavailability of olmesartan from tablets is approximately 28.6%. Olmesartan shows little or no binding to blood cells and has a low risk of clinically significant drug interactions .
Comparative Efficacy and Antihypertensive Effects
Olmesartan demonstrates a rapid and long-lasting inhibition of angiotensin II-induced pressor responses in animal models, with greater potency and faster onset compared to losartan and similar or better efficacy than candesartan cilexetil. Its antihypertensive effects are dose-dependent and most pronounced in high plasma renin models. Hemodynamic studies indicate that olmesartan selectively reduces renal vascular resistance, suggesting that renal vasodilation is a key contributor to its blood pressure-lowering effect 16.
Novel Formulations to Enhance Bioavailability
Olmesartan’s poor aqueous solubility and limited oral bioavailability have led to the development of advanced delivery systems:
- Nanoemulsions: These formulations significantly increase olmesartan’s oral bioavailability (up to 2.8-fold) and provide sustained antihypertensive effects, allowing for lower dosing .
- Transdermal Oleogels: Optimized oleogel formulations enhance drug release and skin permeation, increasing bioavailability by more than 4.5-fold compared to standard gels and 2.5-fold compared to oral tablets, while maintaining stable blood pressure and heart rate .
- Nano-invasomes: Transdermal delivery using nano-invasomes improves skin penetration and increases bioavailability by 1.15 times compared to control formulations .
- Chitosan Nanoparticles for Intranasal Delivery: Intranasal administration of olmesartan-loaded chitosan nanoparticles boosts bioavailability by 11.3-fold over oral suspension and effectively reduces blood pressure and heart rate in hypertensive rats .
Additional Pharmacological Benefits
Beyond its antihypertensive action, olmesartan has shown beneficial effects in animal models of nephrosis, heart failure, and atherosclerosis. It also demonstrates antifibrotic properties by suppressing proliferation and collagen synthesis in activated hepatic stellate cells, suggesting potential in treating liver fibrosis 15. Furthermore, olmesartan exhibits anti-inflammatory and antioxidant effects, as seen in models of ulcerative colitis, where it modulates NF-κB and Nrf2/HO-1 signaling pathways .
Conclusion
Olmesartan is a potent, selective AT1 receptor antagonist with a well-characterized pharmacokinetic profile and a strong antihypertensive effect. Its efficacy can be further enhanced through novel drug delivery systems, which improve bioavailability and therapeutic outcomes. In addition to blood pressure control, olmesartan offers potential benefits in organ protection and anti-inflammatory therapy, broadening its clinical utility.
Sources and full results
Most relevant research papers on this topic